Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcome...
Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Targeted lung denervation (TLD) is a novel bronchoscopic therapy that disrupts parasympathetic pulmonary nerve input to the lung reducing clinical consequences of cholinergic hyperactivity. The AIRFLOW-1 study assessed safety and TLD dose in patients with moderate-to-severe, symptomatic COPD. This analysis evaluated the long-term impact of TLD on C...
Alternative Titles
Full title
Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_896f444ba518432b8cf9ad6ad0a076b4
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_896f444ba518432b8cf9ad6ad0a076b4
Other Identifiers
ISSN
1465-993X,1465-9921
E-ISSN
1465-993X,1465-9921
DOI
10.1186/s12931-021-01664-5
